The Global Companion Animal Drugs Market was valued at USD 26.8 billion in 2025 and is estimated to grow at a CAGR of 6.6% to reach USD 51.1 billion by 2035.
The expansion is driven by the rising adoption of companion animals, an increasing prevalence of chronic and infectious diseases in pets, and the growing willingness of owners to invest in advanced veterinary care. Pet owners increasingly consider their animals as family members, fueling demand for preventive medications, vaccinations, and specialized treatments. The market growth is further supported by the expanding veterinary healthcare infrastructure and increased public awareness of pet health and wellness. Chronic conditions like arthritis, diabetes, cardiovascular disorders, and parasitic infections are common in companion animals, emphasizing the need for effective pharmaceuticals. As veterinary practices embrace innovative therapeutic solutions and preventive care approaches, the demand for companion animal drugs continues to rise globally.
Companion animal drugs include pharmaceuticals, vaccines, and medicated feed additives formulated to prevent, treat, or manage health conditions in pets. These drugs are essential in addressing chronic illnesses, infections, and dermatological conditions, as well as in controlling the spread of contagious diseases among animals.
In 2025, the drugs segment accounted for USD 17.1 billion, driven by increasing cases of chronic illnesses and infections such as arthritis, cancer, and skin conditions. The rising trend of pet humanization has further encouraged investment in advanced veterinary medicines, including antibiotics, anti-inflammatory agents, and parasiticides, to enhance animal well-being.
The dermatology segment is expected to reach USD 17 billion by 2035. High incidence of skin conditions, including allergic dermatitis, parasitic infestations, and bacterial or fungal infections, fuels demand for dermatological treatments. Pets are often susceptible to environmental allergens, food sensitivities, and parasites, which have made anti-allergy medications, antifungals, antibiotics, and parasiticides a vital category within the market.
North America Companion Animal Drugs Market held a 42.9% share in 2025 and is projected to grow at a CAGR of 6.3% through 2035. The regional growth is supported by high pet ownership, advanced veterinary infrastructure, and strong expenditure on pet healthcare. The U.S. contributes significantly to this market due to the rising humanization of pets and increased adoption of preventive and therapeutic treatments.
Key players in the Global Companion Animal Drugs Market include Boehringer Ingelheim International, Zoetis, Elanco Animal Health Incorporated, Vetoquinol, Ceva Santé Animale, Dechra Pharmaceuticals, HIPRA, Indian Immunologicals, Agrolabo, Chanelle Pharma, Endovac Animal Health, Merck, Symrise, Norbrook, and Virbac. Key strategies adopted by companies in the Global Companion Animal Drugs Market include investing heavily in research and development to create innovative and effective pharmaceuticals targeting specific diseases and preventive care solutions. Firms focus on expanding product portfolios across therapeutic areas such as dermatology, cardiology, and endocrinology to meet diverse pet healthcare needs. Partnerships with veterinary clinics, hospitals, and distributors help strengthen market reach and ensure the timely availability of products. Companies also emphasize regulatory compliance, quality assurance, and education programs for veterinarians to enhance adoption. Geographic expansion and targeted marketing campaigns are employed to build brand recognition and boost market share in emerging regions.
This product will be delivered within 2-4 business days.
The expansion is driven by the rising adoption of companion animals, an increasing prevalence of chronic and infectious diseases in pets, and the growing willingness of owners to invest in advanced veterinary care. Pet owners increasingly consider their animals as family members, fueling demand for preventive medications, vaccinations, and specialized treatments. The market growth is further supported by the expanding veterinary healthcare infrastructure and increased public awareness of pet health and wellness. Chronic conditions like arthritis, diabetes, cardiovascular disorders, and parasitic infections are common in companion animals, emphasizing the need for effective pharmaceuticals. As veterinary practices embrace innovative therapeutic solutions and preventive care approaches, the demand for companion animal drugs continues to rise globally.
Companion animal drugs include pharmaceuticals, vaccines, and medicated feed additives formulated to prevent, treat, or manage health conditions in pets. These drugs are essential in addressing chronic illnesses, infections, and dermatological conditions, as well as in controlling the spread of contagious diseases among animals.
In 2025, the drugs segment accounted for USD 17.1 billion, driven by increasing cases of chronic illnesses and infections such as arthritis, cancer, and skin conditions. The rising trend of pet humanization has further encouraged investment in advanced veterinary medicines, including antibiotics, anti-inflammatory agents, and parasiticides, to enhance animal well-being.
The dermatology segment is expected to reach USD 17 billion by 2035. High incidence of skin conditions, including allergic dermatitis, parasitic infestations, and bacterial or fungal infections, fuels demand for dermatological treatments. Pets are often susceptible to environmental allergens, food sensitivities, and parasites, which have made anti-allergy medications, antifungals, antibiotics, and parasiticides a vital category within the market.
North America Companion Animal Drugs Market held a 42.9% share in 2025 and is projected to grow at a CAGR of 6.3% through 2035. The regional growth is supported by high pet ownership, advanced veterinary infrastructure, and strong expenditure on pet healthcare. The U.S. contributes significantly to this market due to the rising humanization of pets and increased adoption of preventive and therapeutic treatments.
Key players in the Global Companion Animal Drugs Market include Boehringer Ingelheim International, Zoetis, Elanco Animal Health Incorporated, Vetoquinol, Ceva Santé Animale, Dechra Pharmaceuticals, HIPRA, Indian Immunologicals, Agrolabo, Chanelle Pharma, Endovac Animal Health, Merck, Symrise, Norbrook, and Virbac. Key strategies adopted by companies in the Global Companion Animal Drugs Market include investing heavily in research and development to create innovative and effective pharmaceuticals targeting specific diseases and preventive care solutions. Firms focus on expanding product portfolios across therapeutic areas such as dermatology, cardiology, and endocrinology to meet diverse pet healthcare needs. Partnerships with veterinary clinics, hospitals, and distributors help strengthen market reach and ensure the timely availability of products. Companies also emphasize regulatory compliance, quality assurance, and education programs for veterinarians to enhance adoption. Geographic expansion and targeted marketing campaigns are employed to build brand recognition and boost market share in emerging regions.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Indication, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Animal Type, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Route of Administration, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Distribution Channel, 2022-2035 ($ Mn)
Chapter 10 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 11 Company Profiles
Companies Mentioned
The companies profiled in this Companion Animal Drugs market report include:- Agrolabo
- Boehringer Ingelheim International
- Ceva Santé Animale
- Chanelle Pharma
- Dechra Pharmaceuticals
- Elanco Animal Health Incorporated
- Endovac Animal Health
- HIPRA
- Indian Immunologicals
- Merck
- Norbrook
- Symrise
- Vetoquinol
- Virbac
- Zoetis
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 148 |
| Published | March 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 26.8 Billion |
| Forecasted Market Value ( USD | $ 51.1 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
